The dupilumab pregnancy registry has identified no signal for birth defects associated with exposure to the biologic during pregnancy, according to Tina Chambers, PhD, MPH, who discussed the surveillance data in a new interview with HCPLive.

The finding matters for a large patient population. Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13 signaling, is a first-line biologic option for moderate-to-severe atopic dermatitis — a chronic inflammatory skin disease that disproportionately affects women of childbearing age. Atopic dermatitis frequently onsets early in life and persists or flares through the reproductive years, which means questions about medication safety in pregnancy arrive in dermatology clinics every week.

Until registry data accumulate, any drug approved relatively recently carries residual uncertainty about fetal risk. Animal reproduction studies can exclude large teratogenic signals, but they cannot substitute for human exposure data collected systematically across trimesters. Pregnancy exposure registries exist precisely to close that gap: they enroll women who took the drug during pregnancy, follow the pregnancies to outcome, and compare the rate of major congenital malformations against expected background rates in the general population.

That is the design behind the findings Chambers described. The registry followed women exposed to dupilumab during pregnancy and evaluated live birth outcomes for structural birth defects. The headline result: no increased rate of birth defects was detected relative to what would be expected in an unexposed population.

Chambers, a perinatal epidemiologist with long experience running pregnancy registries for dermatologic and immunologic therapies, walked through the interpretation of the data in the interview. Her central point is one that clinicians who counsel pregnant patients will recognize: an absence of signal in a registry is reassuring, but the strength of that reassurance depends on the number of exposed pregnancies collected and the precision of the estimate around them.

For dermatologists, the practical question is how to translate "no signal" into counseling at the point of care. Women with moderate-to-severe atopic dermatitis who become pregnant often face a difficult choice between controlling disease activity — which itself carries risks for maternal quality of life, sleep, and infection — and limiting fetal drug exposure. Uncontrolled atopic dermatitis in pregnancy is associated with increased risks of complications, so stopping effective therapy is not a neutral decision. Registry data that show no teratogenic signal help clinicians and patients weigh continuation of therapy on a more informed basis.

The stakes extend beyond atopic dermatitis. Dupilumab holds approvals across a range of type 2 inflammatory conditions, including asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and bullous pemphigoid. That breadth of indication expands the pool of women potentially exposed to the drug during pregnancy, which makes systematic human safety surveillance more valuable with each indication added.

Registry findings also feed directly into drug labeling. As exposure numbers grow and confidence intervals around the malformation rate narrow, manufacturers and regulators can update prescribing information with quantified human data rather than the blanket "there are no adequate and well-controlled studies in pregnant women" language that dominates labels for most biologics.

Chambers's discussion comes at a moment when pregnancy safety data in dermatology is maturing across the entire biologic class. Tumor necrosis factor inhibitors, used in psoriasis and other inflammatory diseases, built a substantial human pregnancy dataset over two decades and now carry reassuring outcome data in labels and guidelines. Interleukin-4/13 blockade is earlier in that lifecycle, and the dupilumab registry represents the structured mechanism by which the same evidentiary standard gets built.

Clinicians should treat the current data as a strong interim reassurance rather than a final verdict. Continued enrollment, longer follow-up of exposed children, and larger denominator numbers will determine whether the absence of a birth defect signal holds — and whether additional outcomes such as preterm birth, low birth weight, and spontaneous abortion track similarly to background rates.

For now, the message Chambers delivered is straightforward: in the pregnancies captured by the registry to date, dupilumab exposure has not produced a detectable increase in major congenital malformations. Dermatology practices managing women who conceive while on the drug — or who need to start it during pregnancy for uncontrolled disease — can factor that evidence into shared decision-making while the registry continues to accrue.